All In Biotech

Free tool

FAERS Monitor: Pheburane

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 216513 or its brand name (Pheburane, Sodium Phenylbutyrate). Reports on generic versions are filed under their own applications.

Reports

177

Serious

122

69% of reports

Hospitalization

60

Death reported

46

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death24
  • off label use21
  • hyperammonaemia20
  • nausea20
  • diarrhoea18
  • decreased appetite16
  • ammonia increased13
  • vomiting13
  • product use complaint12
  • retching12
  • drug ineffective11
  • fatigue10
  • pyrexia9
  • abdominal pain8
  • adverse event7

Reports by year received

View as table
YearReports
20071
20082
20094
20105
20113
201215
20134
20146
20158
20168
20179
20182
20194
20204
20217
202210
202330
202424
202521
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,982 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hyperammonaemiaSignal20477.1315.58,999
ammonia increasedSignal13303.6179.83,615
product use complaintSignal1290.652.4975
retchingSignal1266.938.7715
adverse eventSignal79.04.442
decreased appetiteSignal168.25.195
abdominal painSignal84.12.116
diarrhoeaSignal183.32.128
deathSignal243.32.338
vomitingSignal133.31.919
pyrexiaSignal93.11.611
nauseaSignal203.02.026
off label useSignal212.81.924
fatigue101.50.81
drug ineffective111.00.60

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.